Skip to main content
Log in

Electrophysiologic mechanisms of adverse effects of class I antiarrhythmic drugs (cibenzoline, pilsicainide, disopyramide, procainamide) in induction of atrioventricular re-entrant tachycardia

  • Antiarrhythmic Agent
  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Summary

We evaluated the electrophysiological mechanisms of adverse effects of class I antiarrhythmic drugs (cibenzoline in seven patients, pilsicainide in two, and disopyramide in two, and procainamide in three) in the induction of orthodromic atrioventricular re-entrant tachycardia (AVRT). In 14 patients (10 males, 4 females; mean age 37±18 years) who had inducible AVRT despite the administration of class I drugs, electrophysiological effects of class I antiarrhythmic drugs were evaluated using programmed electrical stimulation techniques. In 4 out of 6 patients with a manifest accessory pathway, class I drugs induced unidirectional conduction block of the accessory pathway (antegrade conduction block associated with preserved retrograde conduction) and enhanced the induction of AVRT with atrial extrastimulation. In eight patients with a concealed accessory pathway, the outward or inward expansion of the tachycardia induction zone was observed in patients who had greater prolongation of the conduction time than the refractory period of the retrograde accessory pathway after class I drugs. During ventricular extrastimulation, the induction of bundle branch reentry after class I drugs initiated the AVRT in patients with either manifest or concealed accessory pathways. We conclude that the adverse effects of class I drugs are mainly due to induction of unidirectional retrograde conduction of the manifest accessory pathway and the greater prolongation of the retrograde conduction time of the concealed accessory pathway than the refractory period, regardless of the subclassification of class I drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Kang PS, Gomes JAC, El-Sherif N, Procainamide in the induction and perpetuation of ventricular tachycardia in man.PACE 1982;5:311–322.

    PubMed  Google Scholar 

  2. Au PK, Bhandari AK, Bream R, Schreck D, Siddiqi R, Rahimtoola SH. Proarrhythmic effects of antiarrhythmic drugs during programmed ventricular stimulation in patients without ventricular tachycardia.J Am Coll Cardiol 1987;9:389–397.

    PubMed  Google Scholar 

  3. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary Report. Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.N Engl J Med 1989; 321:406–410.

    Google Scholar 

  4. Neuss H, Buss J, Schlepper M, et al. Effects of flecainide on electrophysiological properties of accessory pathways in the Wolff-Parkinson-White syndrome.Eur Heart J 1983;4: 347–353.

    PubMed  Google Scholar 

  5. Kerr CR, Prystowsky EN, Smith WM, Cook L, Gallagher JJ. Electrophysiologic effects of disopyramide phosphate in patients with Wolff-Parkinson-White syndrome.Circulation 1982;65:869–878.

    PubMed  Google Scholar 

  6. Eldar M, Ruder MA, Dovis JC, et al. Procainamide-induced incessant supraventricular tachycardia in the Wolff-Parkinson-White syndrome.PACE 1986;9:652–659.

    PubMed  Google Scholar 

  7. Fujiki A, Mizumaki K, Tani M, Yoshida S, Sasayama S. Electrophysiologic effects and efficacy of cibenzoline in patients with supraventricular tachycardia.J Cardiovasc Pharmacol 1992;20:375–379.

    PubMed  Google Scholar 

  8. Cockrell JL, Scheinman MM, Titus C, et al. Safety and efficacy of oral flecainide therapy in patients with atrioventricular re-entrant tachycardia.Ann Intern Med 1991;114: 189–194.

    PubMed  Google Scholar 

  9. Klein GJ, Bashore TM, Sellers TD, Pritchett ELC, Smith WM, Gallagher JJ. Ventricular fibrillation in the Wolff-Parkinson-White syndrome.N Engl J Med 1979;301: 1080–1085.

    PubMed  Google Scholar 

  10. Akhtar M, Lehmann MH, Denker ST, Mahmud R, Tchou P, Jazayeri M. Electrophysiologic mechanisms of orthodromic tachycardia initiation during ventricular pacing in the Wolff-Parkinson-White syndrome.J Am Coll Cardiol 1987; 9:89–100.

    PubMed  Google Scholar 

  11. Kuck KH, Schluter M, Geiger M, Siebels J, Duckeck W. Radiofrequency current eatheter ablation of accessory atrioventricular pathways.Lancet 1991;337:1557–1561.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fujiki, A., Tani, M., Yoshida, S. et al. Electrophysiologic mechanisms of adverse effects of class I antiarrhythmic drugs (cibenzoline, pilsicainide, disopyramide, procainamide) in induction of atrioventricular re-entrant tachycardia. Cardiovasc Drug Ther 10, 159–166 (1996). https://doi.org/10.1007/BF00823594

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00823594

Key words

Navigation